Skip to main content
Press Releases

Cidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016

By April 6, 2016No Comments

Presentations to Highlight Results from the Phase 1 Study of Novel
Echinocandin CD101 IV Demonstrating Excellent Safety and Supporting
Once-Weekly Dosing

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives and immunotherapies to treat fungal and
other infections, today announced that data from preclinical and
clinical studies of its novel echinocandin, CD101, will be presented at
the 26th annual European Congress of Clinical Microbiology
and Infectious Diseases (ECCMID) in Amsterdam, April 9-12, 2016.
Specifically, Cidara’s presentations will feature results from the
successful Phase 1 dose-escalation study of CD101 IV as well as provide
an update on the company’s anti-infective product pipeline, including
key clinical and regulatory milestones for CD101 and the CloudbreakTM
immunotherapy platform.

“Cidara’s presentations at this year’s ECCMID reinforce our commitment
to developing novel antifungal therapies to fight serious infections
that are becoming increasingly resistant to current standards of care,”
said Jeff Stein, Ph.D., president and CEO of Cidara. “Results from our
recently completed Phase 1 studies demonstrated that CD101 IV can be
safely dosed once weekly at high drug exposures. We expect this to
translate to a safe once-weekly treatment for both inpatients and
outpatients, especially those with fungal infections that are difficult
to treat with existing therapies. We are excited to share data from both
of our CD101 programs and our Cloudbreak platform with ECCMID attendees.”

The ECCMID presentations are as follows:

Oral Presentations:

Sunday, April 10: Pipeline Talk (1:00 p.m. – 2:00 p.m. CET, Pipeline

  • Cidara Pipeline; T. Sandison

Monday, April 11: Oral Session OS102: Challenges in antifungal
treatment (11:30 a.m. – 12:30 p.m. CET, Hall K)

  • O425: The safety and single-dose
    pharmacokinetics of CD101 IV: results from a phase 1, dose-escalation
    study; D. Thye

Poster Presentation:

Tuesday, April 12: Poster Session: Antifungal drug treatment (12:30
p.m. – 1:30 p.m. CET, Poster Area)

  • P1578: Allometric scaling and the
    chimpanzee as a surrogate for human pharmacokinetics of CD101, a novel
    echinocandin; V. Ong

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel anti-infectives
for the treatment of diseases that are inadequately addressed by current
standard-of-care therapies. Cidara’s initial product portfolio comprises
two formulations of the company’s novel echinocandin, CD101. CD101 IV is
being developed as a once-weekly high exposure therapy for the treatment
and prevention of serious, invasive fungal infections. CD101 topical is
for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC
(RVVC), a prevalent mucosal infection. In addition, Cidara has developed
a proprietary immunotherapy platform, Cloudbreak™, designed to create
compounds that direct a patient’s immune cells to attack and eliminate
pathogens that cause infectious disease. Cidara is headquartered in San
Diego, California. For more information, please visit

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101 IV and CD101
topical, and their potential to treat infections, as well as the
intended design of current and future Cloudbreak compounds. Risks that
contribute to the uncertain nature of the forward-looking statements
include: the success and timing of Cidara’s preclinical studies and
clinical trials; regulatory developments in the United States and
foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-K most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were

Westwicke Partners, LLC
Robert H. Uhl

Sam Brown Inc.
Mike Beyer